|1.||Iwamoto, Jun: 9 articles (05/2014 - 09/2003)|
|2.||Sato, Yoshihiro: 6 articles (03/2013 - 01/2005)|
|3.||Takeda, Tsuyoshi: 6 articles (09/2012 - 09/2003)|
|4.||Ohyashiki, Kazuma: 5 articles (09/2010 - 09/2003)|
|5.||Miyazawa, Keisuke: 5 articles (09/2010 - 09/2003)|
|6.||Ozaki, Iwata: 4 articles (12/2012 - 02/2006)|
|7.||Eguchi, Yuichiro: 4 articles (12/2012 - 02/2006)|
|8.||Mizuta, Toshihiko: 4 articles (12/2012 - 02/2006)|
|9.||Matsumoto, Hideo: 4 articles (09/2012 - 01/2009)|
|10.||Yamamoto, Kyosuke: 3 articles (01/2011 - 02/2006)|
01/01/1999 - "Administration of menatetrenone at a dose effective in improving osteoporosis may also be useful in restoring hematopoiesis in MDS patients, possibly by way of inducing differentiation."
05/01/2014 - "The present review study aimed to clarify the effect of menatetrenone on the skeleton in postmenopausal women with osteoporosis, by reviewing the results of randomized controlled trials (RCTs) in the literature. "
01/01/2009 - "In conclusion, menatetrenone therapy was not effective for preventing vertebral fractures in the full analysis set of this study, but the results suggested that it may prevent vertebral fractures in patients with more advanced osteoporosis."
05/01/2014 - "This review of the literature revealed positive evidence for the effects of menatetrenone monotherapy on fracture incidence in postmenopausal women with osteoporosis. "
05/01/2014 - "RCTs that investigated the effect of menatetrenone on bone mineral density (BMD), measured by dual-energy X-ray absorptiometry and fracture incidence in postmenopausal women with osteoporosis, were identified by a PubMed search for literature published in English. "
|2.||Hip Fractures (Intertrochanteric Fractures)
01/01/2009 - "The present meta-analysis of three RCTs suggests that there is efficacy for menatetrenone treatment against non-vertebral and hip fractures among patients with neurological diseases. "
01/01/2009 - "A literature search was conducted on PubMed from January 1995 to July 2008 to identify randomized controlled trials (RCTs) of use of menatetrenone against non-vertebral and hip fractures in patients with neurological diseases. "
01/01/2009 - "According to the meta-analysis, the overall relative risks (95% confidence intervals) for non-vertebral and hip fractures with menatetrenone treatment compared with non-treatment were 0.13 (0.05, 0.35) and 0.14 (0.05, 0.43), respectively, in patients with neurological diseases. "
01/01/2009 - "The purpose of the present study was to clarify the efficacy of menatetrenone (vitamin K(2)) against non-vertebral and hip fractures in patients with neurological diseases. "
01/01/2009 - "Efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases: meta-analysis of three randomized, controlled trials."
|3.||Metabolic Bone Diseases (Osteopenia)
02/15/2002 - "Finally, these findings implicated the therapeutic usefulness of menatetrenone on a moderate degree of bone abnormality such as drug-induced osteopenia."
09/01/1998 - "Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients."
05/01/2003 - "Effects of menatetrenone on the bone and serum levels of vitamin K2 (menaquinone derivatives) in osteopenia induced by phenytoin in growing rats."
06/01/2002 - "Overexpression of granulocyte colony-stimulating factor induces severe osteopenia in developing mice that is partially prevented by a diet containing vitamin K2 (menatetrenone)."
05/01/2013 - "We aimed to evaluate the clinical efficacy of monotherapy with alendronate and combined therapy with alendronate and menatetrenone (vitamin K2 [VitK2]) in postmenopausal rheumatoid arthritis (RA) patients with osteoporosis or osteopenia. "
|4.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/01/1999 - "Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog."
01/01/2002 - "Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome."
02/01/2002 - "We administered a vitamin K2 analog, menatetrenone, at 45 mg daily to 23 patients with myelodysplastic syndrome (MDS): 13 patients with RA, 2 with RARS, 6 with RAEB and 2 with RAEB-T. "
09/01/2010 - "We performed an open-labeled single-arm prospective phase II clinical trial of vitamin K(2) (menatetrenone: VK2) monotherapy and VK2 plus 1alpha-hydroxyvitamin D(3) (alfacalcidol: VD3) combination therapy for myelodysplastic syndromes (MDS) with refractory anemia and refractory cytopenia with multilineage dysplasia, having either low or intermediate-1 risks of the IPSS. "
09/01/2002 - "Menatetrenone (MK-4) inhibits bone resorption and enhances osteoblast-induced mineralization. "
02/01/1995 - "These findings suggest that the inhibitory effect of menatetrenone on bone resorption is not due to gamma-carboxylation and that the side chain of menatetrenone may play an important role in this inhibitory effect."
05/01/1993 - "These results indicate that menatetrenone may inhibit bone resorption through at least two different mechanisms; one possibly is an inhibitory effect on prostaglandin production."
05/01/1999 - "Inhibitory effect of vitamin K2 (menatetrenone) on bone resorption in ovariectomized rats: a histomorphometric and dual energy X-ray absorptiometric study."
12/01/2005 - "Recently, it has been reported that the inhibitory effect of vitamin K(2) (menatetrenone) on bone resorption may be related to its side chain. "
|1.||Vitamin K 2 (Vitamin K2)
|4.||risedronic acid (risedronate)
|6.||Alendronate (Alendronate Sodium)
|8.||vitamin MK 7
|9.||Etidronic Acid (HEDP)
|10.||Vitamin K 1 (Phylloquinone)